Amivantamab

WOBURN, Mass., July 30, 2026 Replimune Group, Inc. announced a favorable outcome from the U.S. Food and Drug Administration’s...

SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...

HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...

RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...

CHICAGO, Ill., May 29, 2026 Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study,...

RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...